Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

New Health Campaign Urges People With Diabetes To 'TALK Hypos'


News provided by

Novo Nordisk and Diabetes UK

25 Sep, 2014, 08:00 GMT

Share this article

Share toX

Share this article

Share toX

This image opens in the lightbox
Today marks the launch of the TALK Hypos awareness campaign, supported by Novo Nordisk and Diabetes UK, which aims to encourage people with diabetes to report hypoglycaemia (hypos) to their doctor or nurse. The TALK Hypos campaign launches to coincide with Hypo Awareness Week (29 Septemberâeuro"5 October 2014). (PRNewsFoto/Novo Nordisk and Diabetes UK)

GATWICK, England, September 25, 2014 /PRNewswire/ --

- Potentially dangerous diabetes symptom currently goes unreported to healthcare professionals

Today marks the launch of the TALK Hypos awareness campaign, supported by Novo Nordisk and Diabetes UK, which aims to encourage people with diabetes to report hypoglycaemia (hypos) to their doctor or nurse. The TALK Hypos campaign launches to coincide with Hypo Awareness Week (29 September-5 October 2014).

     (Photo: http://photos.prnewswire.com/prnh/20140925/708409 )

There are about 3.2 million people diagnosed with diabetes in the UK[1] and hypos are one of the most common diabetes complications.[2] Hypos are when glucose in the blood falls to a low level, and symptoms can include a pounding heart, trembling, hunger, difficulty concentrating and blurred vision.[3] Left untreated, hypos can become serious and cause unconsciousness.[4] Despite this, hypos remain under-recognised[5] and under-reported[6] by patients.

Simon O'Neill, Director of Health Intelligence for Diabetes UK, said, "People with diabetes can fail to report hypos to clinicians for a range of reasons, including lack of awareness, a fear of losing their driving licence and a belief that their healthcare professional is unable to make a difference. To make matters worse, we know that people with diabetes and their families are often fearful of hypos and feel powerless to do anything.

"The first step is to help people with diabetes recognise the symptoms of hypos and better manage their condition by encouraging a regular discussion about them during consultations. We are pleased to be involved in a campaign which aims to do just that."

TALK Hypos provides an acronym to encourage people with diabetes to discuss hypoglycaemia with their doctor or nurse:

  • THINK: Do you know what a hypo is? Do you suffer from hypos?
  • ASK: your doctor or nurse about hypos and discuss them as part of your consultation
  • LEARN: what can be done to better manage your hypos, including lifestyle and treatment options
  • KEEP: track of your hypos for discussion with your healthcare professional

As well as the more immediate symptoms, a few people may experience severe hypos, which can require emergency assistance. Regularly occurring severe hypos have been linked to longer-term health complications including, in some instances, heart disease.[6] Having repeated hypos can, over time, lead to 'hypo unawareness', where the warning symptoms of a hypo are no longer felt, making hypos harder to identify and more difficult to manage.[6]

Simon O'Neill added, "We would encourage all people with diabetes to remember the simple TALK Hypos message and to remember that steps can be taken to better manage hypos, including simple changes to lifestyle, diet and treatment. It is very important to discuss hypos as part of the regular consultation with your doctor or nurse."

Klaus Henning Jensen, Director of Clinical, Medical and Regulatory, Novo Nordisk, said, "Novo Nordisk is proud to support the TALK Hypos campaign, which aims to improve awareness of hypos as part of Changing Diabetes®; a global commitment to improving conditions for the millions of people who live with diabetes around the world today, and those who are at risk of developing diabetes tomorrow."

The TALK Hypos campaign comprises patient education materials and an education video that is hosted on the Diabetes UK and Novo Nordisk websites.

Notes to the editor:  

To access the TALK Hypos campaign materials via the Novo Nordisk website, please visit: http://www.novonordisk.co.uk.

About Novo Nordisk  

Headquartered in Denmark, Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit novonordisk.co.uk.

About Diabetes UK 

Diabetes UK is the leading UK charity that cares for, connects with and campaigns on behalf of all people affected by and at risk of diabetes. For more information on all aspects of diabetes and access to Diabetes UK activities and services, visit http://www.diabetes.org.uk.

About Changing Diabetes® 

Today, 382 million people in the world are living with diabetes, which is predicted to rise to 592 million in less than 25 years.[7] Changing Diabetes® is the Novo Nordisk global commitment to improve conditions for the millions of people who live with diabetes around the world today, and those who are at risk of developing diabetes tomorrow.

About Diabetes  

Diabetes (or diabetes mellitus) is a serious and challenging health condition that develops when there is too much sugar in the blood due to the body being unable to produce or respond to the hormone, insulin, in the normal way.[8] Over 3 million people have already been diagnosed with diabetes in the UK, and this figure is projected to rise to 5 million by 2025.[1],[9]

There are two main types of diabetes. For people with type 1 diabetes, the body's immune system destroys the cells that produce insulin. People with type 1 diabetes therefore need insulin injections for the rest of their lives. About 10% of all people with diabetes have type 1.[8]

Type 2 diabetes is where the body does not produce enough insulin, or the body's cells do not react to insulin. This is known as insulin resistance. The symptoms of type 2 diabetes can sometimes be controlled by exercise and eating a healthy diet and monitoring blood glucose levels, but if the condition gets worse over time, it may need to be managed by medication.[8]

1. Diabetes UK. Diabetes Prevalence 2013: Key statistics on diabetes. Available at: http://www.diabetes.org.uk/About_us/What-we-say/Statistics/Diabetes-prevalence-2013. Accessed: August 2014.

2. Diabetes.co.uk. Short Term Complications. Available at: http://www.diabetes.co.uk/diabetes-complications/short-term-complications.html. Accessed: September 2014.

3. Cefalu C, et al. Controlling hypoglycemia in type 2 diabetes: Which agent for which patient? J Fam Pract. 2005;54(10):855-62.

4. Diabetes.co.uk. Severe hypoglycaemia. Available at: http://www.diabetes.co.uk/severe-hypoglycemia.html. Accessed: August 2014.

5. Kenny, C. When hypoglycemia is not obvious: Diagnosing and treating under-recognized and undisclosed hypoglycemia. Primary Care Diabetes. 2014;8:3-11.

6. Bailey C, Day C. Hypoglycaemia: a limiting factor. Br J Diabetes Vasc Dis. 2010;10:2-4.

7. International Diabetes Federation. IDF Diabetes Atlas, 6th Edition, 2013 Update. Brussels, Belgium: International Diabetes Federation. Available from: http://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf. Accessed: August 2014.

8. NHS Choices. Diabetes introduction. Available at: http://www.nhs.uk/Conditions/Diabetes/Pages/Introduction.aspx. Accessed: August 2014.

9. Diabetes UK. State of the Nation 2013. Available at: http://www.diabetes.org.uk/Documents/About%20Us/What%20we%20say/0160b-state-nation-2013-england-1213.pdf . Accessed: August 2014.

For more information, please contact Liz Skrbkova or Rebecca Hess at Novo Nordisk.


UK Media:

Liz Skrbkova
+44(0)1293-762129
+44(0)7919-590622 
lzsk@novonordisk.com

Rebecca Hess
+44(0)1293-762103
+44(0)7725-498451
rcme@novonordisk.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.